2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Breast Neoplasms
395
Neoplasms
350
Carcinoma, Non-Small-Cell Lung
313
Prostatic Neoplasms
264
Colorectal Neoplasms
236
Lung Neoplasms
204
Multiple Myeloma
163
Pancreatic Neoplasms
147
Ovarian Neoplasms
146
Neoplasm Metastasis
141
Leukemia, Myeloid, Acute
138
Melanoma
118
Squamous Cell Carcinoma of Head and Neck
100
Carcinoma, Renal Cell
93
Stomach Neoplasms
92
Recurrence
92
Lymphoma
91
Lymphoma, Non-Hodgkin
89
Endometrial Neoplasms
89
Carcinoma, Hepatocellular
89
Precursor Cell Lymphoblastic Leukemia-Lymphoma
87
Glioblastoma
85
Brain Neoplasms
84
Head and Neck Neoplasms
77
Glioma
76
Uterine Cervical Neoplasms
75
Urinary Bladder Neoplasms
72
Sarcoma
70
Leukemia, Lymphocytic, Chronic, B-Cell
70
Hematologic Neoplasms
68
Interventions
atezolizumab
2
Etoposide
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Small Cell Lung Cancer Extensive Stage
×
30 days
×
Clear all
NCT05703971
2026-06-03
Acclaim-3
Genprex, Inc.
Phase 1/2
Recruiting
62 enrolled
NCT07227597
2026-05-28
MK-6070-003
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
170 enrolled